Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

SLOUGH, England and RICHMOND, Va., April 16, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release) ...

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

Sublocade (buprenorphine) is a brand-name subcutaneous injection prescribed for opioid use disorder. It works to help reduce the need for opioids by acting in certain areas of the brain called mu and ...

Evidence demonstrates that SUBLOCADE supports long-term recovery from opioid use disorder (OUD) and is effective and safe. Publications highlight the importance of overcoming access barriers to ...

Monthly injections work great. Patients come in once a month, get their shot, and can focus on the rest of their treatment.” — Samantha Callister, Executive Director Integrity Treatment Partners ...

Add Yahoo as a preferred source to see more of our stories on Google. Dr. Andrew Herring, who works in the addiction clinic at Highland Hospital in Oakland, Calif., says that Sublocade, an injectable ...